Literature DB >> 16608665

Once-daily therapies for the treatment of HIV infection.

Karen T Tashima1, Jennifer Adelson Mitty.   

Abstract

For patients initiating antiretroviral therapy, there are several well-tolerated once-daily regimens from which to choose. Once-daily antiretroviral therapy may be ideal for patient adherence and convenience. However, results of a few recent clinical trials exploring new once-daily regimens have shown that one cannot assume that any three-drug combination will be successful. Once-daily therapy options for treatment-experienced patients are more limited but may be successful depending on prior antiretroviral treatment exposure and resistance mutations. Current approaches to once-daily therapy include simplifying successful regimens and investigating novel antiretroviral agents with long half-lives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608665     DOI: 10.1007/s11904-006-0023-0

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  35 in total

Review 1.  Impact of once- and twice-daily dosing regimens on adherence and overall safety.

Authors:  Trevor Hawkins
Journal:  AIDS Read       Date:  2004-06

2.  Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.

Authors:  Agathe León; Esteban Martinez; Josep Mallolas; Montserrat Laguno; Jose Luis Blanco; Tomás Pumarola; Josep María Gatell
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

3.  Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.

Authors:  Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2005-10-25       Impact factor: 5.226

Review 4.  The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing.

Authors:  David J Back; David M Burger; Charles W Flexner; John G Gerber
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

5.  Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.

Authors:  Desmond Maitland; Graeme Moyle; James Hand; Sundhiya Mandalia; Marta Boffito; Mark Nelson; Brian Gazzard
Journal:  AIDS       Date:  2005-07-22       Impact factor: 4.177

6.  The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Authors:  P Cardiello; P Srasuebkul; E Hassink; A Mahanontharit; T Samor; K Ruxrungtham; J Lange; D Cooper; P Phanuphak
Journal:  HIV Med       Date:  2005-03       Impact factor: 3.180

7.  A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use.

Authors:  K T Tashima; J W Hogan; L I Gardner; C Korkontzelou; E E Schoenbaum; P Schuman; A Rompalo; C C Carpenter
Journal:  Clin Infect Dis       Date:  2001-11-07       Impact factor: 9.079

8.  Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.

Authors:  D T Jayaweera; M A Kolber; M Brill; T Tanner; R Campo; A Rodriguez; H-M Chu; V Garg
Journal:  HIV Med       Date:  2004-09       Impact factor: 3.180

9.  Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

Authors:  Edwin DeJesus; Debra McCarty; Charles F Farthing; Denise D Shortino; Beatriz Grinsztejn; Deborah A Thomas; Shannon R Schrader; Steve A Castillo; Michael G Sension; Kevin Gough; Sam J Madison
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.

Authors:  Valerie E Stone; Jamie Jordan; Jerry Tolson; Robert Miller; Tom Pilon
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

View more
  2 in total

1.  When drugs don't work: economic assessment of enhancing compliance with interventions supported by electronic monitoring devices.

Authors:  Dyfrig Hughes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Effect of once-daily FDC treatment era on initiation of cART.

Authors:  David M Mosen; Michael Horberg; Douglas Roblin; Christina M Gullion; Richard Meenan; Wendy Leyden; Weiming Hu
Journal:  HIV AIDS (Auckl)       Date:  2010-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.